Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02758431 · ClinicalTrials.gov registry record · NA
Cardiovascular Outcomes of Low Testosterone
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 232
- Enrollment target
NCT02758431: Completed NA study, sponsored by University of Colorado, Denver.
NCT02758431 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 232 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02758431, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 232 participants
- Enrollment target
Study Summary
This study plans to learn more about heart and vascular aging in men. In some men as they get older, testosterone levels fall below the normal range for young men. Also, as men get older cardiovascular health worsens. This can lead to high blood pressure and heart disease. In this study we want to find out what causes cardiovascular health to worsen in older men. Also we want to find out what happens when testosterone levels are lowered for a short time. Specifically, we want to see if the reduction in cardiovascular health in older men with low testosterone levels is because of damage to mitochondria. Mitochondria are the main power supply of the cells in our body. The results from this study will help to understand why cardiovascular health declines in older men with low testosterone levels compared to younger men and older men who have higher testosterone levels. Knowing this information will help to develop therapies to prevent heart disease in men.
Primary Outcome
Brachial artery flow-mediated dilation, and EndoPAT™
Interventions
- DRUG Placebo Tablet
- DRUG Placebo Gel
- DRUG Acyline
- DRUG Testosterone Gel
- DRUG Arimidex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2023-01-04 |
| Phase | NA |
What the finished NCT02758431 record still lists
NCT02758431 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo Tablet is the first listed.
NCT02758431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02758431 about?
NCT02758431 is a clinical study titled "Cardiovascular Outcomes of Low Testosterone". This study plans to learn more about heart and vascular aging in men. In some men as they get older, testosterone levels fall below the normal range for young men. Also, as men get older cardiovascular health worsens. This can lead to high blood pressure and heart disease. In this study we want to f...
What is the current status of trial NCT02758431?
This trial is currently completed. It is a NA study. The enrollment target is 232 participants. The study started on 2016-07-01. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT02758431?
The interventions under investigation include: Placebo Tablet (DRUG), Placebo Gel (DRUG), Acyline (DRUG), Testosterone Gel (DRUG), Arimidex (DRUG).
Who is sponsoring clinical trial NCT02758431?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02758431's enrollment target sits among peer trials
232 463rd of 2000 higher than 1,536 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI